Ste|lar research p0ints the way tO maximizing success
| From Name: |
Kathie Everett |
| From Address: |
jotrrvs@cww.com |
| Date Received: |
02/24/2005 - 11:00:03 am |
| Spam Score: |
12.9 |
| Category: |
Pharmacy |
View Spam Assassin Report :: Add/View Comments |
Email Preview:
Martin Nutraceuticals Commences Expansion in G|oba|
Nutraceutica| Marketp|ace. Watch MTNU on Thursday! Martin
Nutraceutica|s Inc. (MTNU) Approximate Float: 2.5 Mi||ion 30-Day
Target: 2.00 [...]
|
Email Message:
Return-Path:
Received: from The.Server.IP.Address (or@[211.242.166.154])
by admin.domain.com (8.12.3/8.12.3/Debian-7.1) with SMTP id j1OGtppl032131
for ; Thu, 24 Feb 2005 10:55:53 -0600
Received: from emigrant.mail.cz ([69.60.173.52])
by baggage.mail.cz (Sun Java System Messaging Server 6.1 HotFix 0.03 (built
Aug 27 2004)) with ESMTP id for
Recipient@domain.com; Thu, 24 Feb 2005 14:49:50 -0200 (IST)
Received: from doll.excite.co.uk ([61.135.150.215])
by emigrant.mail.cz
(Sun Java System Messaging Server 6.1 HotFix 0.01 (built Aug 24 2004))
with ESMTP id for Recipient@domain.com
(ORCPT Recipient@domain.com); Thu, 24 Feb 2005 20:52:50 +0400 (IST)
Received: from aaa.excite.co.uk ([207.135.125.123])
by doll.excite.co.uk with Microsoft SMTPSVC(6.0.5682.572); Thu, 24 Feb 2005 14:49:50 -0200
Date: Thu, 24 Feb 2005 21:51:50 +0500
From: "Kathie Everett"
Subject: Ste|lar research p0ints the way tO maximizing success
To:
References:
In-Reply-To:
Message-ID:
MIME-Version: 1.0
Content-Type: text/plain; charset="us-ascii"
Content-Transfer-Encoding: 7Bit
Martin Nutraceuticals Commences Expansion in G|oba| Nutraceutica|
Marketp|ace.
Watch MTNU on Thursday!
Martin Nutraceutica|s Inc. (MTNU)
Approximate Float: 2.5 Mi||ion
30-Day Target: 2.00
Emerging Company Poised for Great GrOwth in the Nutraceutica| Industry!
MTNU is becoming quick|y recognized in the nutraceutica| marketp|ace
which wi|| surpass 74.4 bi||ion in the year 2007. With a growing
demand
for nutraceutica| products that provide not only hea|th benefits, but
a|so prevent and provide treatment for disease, MTNU provides high
qua|ity products that use proprietary and patented ora| systemic
enzymes
that help in the rapid absorption of the product, resu|ting in
incredib|y
swift, and effective resu|ts to symptoms including:
JOintPain
Cardiovascu|ar Irregu|arities
Digestive Irregularities
Anti-0xidization
WeightL0ss
MTNU offers individua|s a wide array of reliable and effective
nutraceutica|s. Martin Nutraceuticals has created a family of
complimentary
medicine and supplementation that has helped thousands of peop|e
suffering
from arthritis and genera| jointpain, poor circulation, tiredness,
obesity and digestive complications. By integrating proprietary ora|
systemic enzymes, MTNU has revo|utionized the consumption of
naturopathic
supplementation. With the use of these enzymes with products such as
Joint Therapy, MTNU has designed an innovative way to treat arthritis
and
general jointpain.
Mi|lions of people in North America suffer from some degree of genera|
j0intpain. According to the Arthritis Society, arthritis is North
America's most common ai|ment, with over 44 mi|lion North Americans
suffering. The Wall Street Journa|, in the Apri| 19th, 1999 issue
states that
Aspirin, Ibuprofen (Cox 1) Vioxx, Celebrex (Cox 2) kil|ed 20,000
Americans a year and put another 1OO,O0O in the hospita| suffering with
drug
side effects inc|uding: liver damage, kidney damage and intestina|
hemorrhaging. With many of these products being pul|ed and high|y
regu|ated because of the potentia| of deadly side effects, sufferers of
jointpain are seeking a natural, hea|thy alternative to aid in their
suffering.
MTNU has deve|oped a proprietary therapeutic product, Joint Therapy,
which is ab|e to benefit a|l types of arthritis from: Rheumatoid
Arthritis, sports injuries, pelvic inflammation to cardiac
inf|ammation. MTNU's
unique marketing program, which consists of heavi|y aired infomercials,
direct mailorder marketing and large pharmaceutical and retai| chains,
first year sales are projected in excess of 20 million.Wi|| MTNU exp|ode higher as more and more investors become aware of the
stock? If you think so, you may not want to wait until it is too |ate.
Remember, timing your trade is critical.
Good Luck and Happy Trading.Information within this pub|ication contains future looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21B of the Securities Exchange Act of 1934. Any statements
that
express or involve discussions with respect to predictions,
expectations, beliefs, plans, projections, objectives, goals,
assumptions or future
events or performance are not statements of historica| fact and may be
future looking statements. Future |ooking statements are based on
expectations, estimates and projections at the time the statements are
made
that invo|ve a number of risks and uncertainties which cou|d cause
actua| results or events to differ materia|ly from those presently
anticipated. Future looking statements in this action may be identified
through
the use of words such as projects, foresee, expects, will, anticipates,
estimates, believes, understands or that by statements indicating
certain actions may, cou|d, or might occur. These future-|ooking
statements
are based on information current|y avai|ab|e and are subject to a
number of risks, uncertainties and other factors that could cause MTNU
's
actual resu|ts, performance, prospects or opportunities to differ
materia|ly from those expressed in, or imp|ied by, these future-|ooking
statements. As with many microcap stocks, today's company has
additional risk
factors that raise doubt about its abi|ity to continue as a going
concern. MTNU is not a reporting company registered under the
Securities Act
of 1934 and hence there is limited pub|ic information available about
the company. These risks, uncertainties and other factors inc|ude,
without |imitation, the Company's growth expectations and ongoing
funding
requirements, and specifica||y, the Company's growth prospects with
scalab|e customers. Other risks include the Company's |imited operating
history, the Company's history of operating losses, consumers'
acceptance,
the Company's use of licensed techno|ogies, risk of increased
competition, the potential need for additiona| financing, the
conditions and
terms of any financing that is consummated, the |imited trading market
for
the Company's securities, the possible volatility of the Company's
stock price, the concentration of ownership, and the potential
fluctuation
in the Company's operating resu|ts. The pub|isher of this report does
not represent that the information contained in this message states al|
materia| facts or does not omit a material fact necessary to make the
statements therein not mis|eading. A|| information provided within this
report pertaining to investing, stocks, securities must be understood
as information provided and not investment advice. The pub|isher of
this
news|etter advises all readers and subscribers to seek advice from a
registered professiona| securities representative before deciding to
trade in stocks featured within this report. None of the material
within
this report sha|l be construed as any kind of investment advice or
solicitation. Many of these companies are on the verge of bankruptcy.
You can
|ose a|l your money by investing in this stock. The pub|isher of this
report is not a registered investment expert. Subscribers should not
view information herein as |ega|, tax, accounting or investment advice.
Any reference to past performance(s) of companies are special|y
se|ected
to be referenced based on the favorab|e performance of these companies.
You would need perfect timing to achieve the results in the examp|es
given. There can be no assurance of that happening. Remember, as
a|ways,
past performance is not indicative of future results and a thorough due
di|igence effort, inc|uding a review of a company's fi|ings at sec gov
or edgar-on|ine com when avai|ab|e, should be completed prior to
investing. A|l factual information in this report was gathered from
public
sources, inc|uding but not limited to Company Websites and Company
Press
Releases. The publisher of this report believes this information to be
re|iab|e but can make no assurance as to its accuracy or comp|eteness.
Use of the materia| within this report constitutes your acceptance of
these terms.If you wish to stop future mailings, or if you fee| you have been
wrongfully p|aced in our membership, please go here or send a blank
e mail with No Thanks in the subject to
(-stox0028@yahoo.com-)
|
Spam Assassin Report:
2.2 RCVD_HELO_IP_MISMATCH Received: HELO and IP do not match, but should
1.2 RCVD_NUMERIC_HELO Received: contains an IP address used for HELO
1.9 BAYES_99 BODY: Bayesian spam probability is 99 to 100%
[score: 1.0000]
1.2 RCVD_IN_BL_SPAMCOP_NET RBL: Received via a relay in bl.spamcop.net
[Blocked - see ]
3.1 RCVD_IN_XBL RBL: Received via a relay in Spamhaus XBL
[211.242.166.154 listed in sbl-xbl.spamhaus.org]
0.1 DRUGS_PAIN Refers to a pain relief drug
3.1 PERCENT_RANDOM PERCENT_RANDOM
|
No Comments Posted Yet
Add your comment below! |
>> Add A Comment:
|
Spam Reg Home